Plain-English translation of NCT07069725 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called in people with advanced liver fibrosis (severe scarring of the liver). Researchers will give participants the medication and use special PET imaging scans to see how the drug affects liver tissue and whether it can help reduce the scarring process.
Advanced liver scarring can lead to serious complications and liver failure. This medication is being investigated because it may slow or reverse the scarring process, but doctors need to understand how it works in the body first before testing whether it actually improves patients' health.
Participation happens in two main parts. In Part A, you'll come to the trial site for blood tests and a special PET imaging scan using a radioactive tracer to see how your liver works. Depending on those results, you may be invited to continue in Part B, where you'll take the medication and have additional PET scans and blood tests over several visits to see how the treatment affects your liver. The entire trial involves multiple visits to the research center and careful monitoring for safety.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Sweden
Phase
Safety & dosing
Sponsor
AstraZeneca
Collaborators
CTC Clinical Trial Consultants AB, Karolinska Institutet
Enrollment target
~8 participants
Started
May 2025
Primary completion
July 2026
Age range
20 Years and older
Last updated on clinicaltrials.gov in July 2026.